Johnson & Johnson (J&J) has expanded its partnership with the US Department for Health and Human Service (HSS)’s Biomedical Advanced Research and Development Authority (BARDA) to commit more than $1bn to co-fund research and development (R&D), as well as clinical testing, of Covid-19 vaccines.
This builds upon an existing partnership between J&J and BARDA to develop anti-viral drugs against the novel coronavirus.
This part of the partnership will also receive additional funding; the precise amount was not disclosed. As part of the new deal, J&J will leverage its subsidiary Janssen’s proprietary vaccine platform, AdVac , and expand its manufacturing capabilities to be able to supply one billion doses of a vaccine globally.